• Applied Strategies Using (-)-Blebbistatin for Cytoskeletal D

  2026-07-23

  (-)-Blebbistatin, a potent non-muscle myosin II inhibitor, enables precise modulation of actin-myosin interactions for advanced mechanobiology and cardiac contractility studies. This article delivers actionable workflow refinements, comparative advantages, and troubleshooting guidance, empowering researchers to extract reproducible, high-sensitivity data across cytoskeletal, cardiac, and cell migration models.

• Pandemic Box Compounds for MDR Pathogen Control: In Vitro In

  2026-07-23

  This study systematically evaluated MMV Pandemic Response Box compounds against multidrug-resistant (MDR) bacterial and fungal clinical isolates, identifying several agents with potent in vitro activity against pathogens such as A. baumannii and P. aeruginosa. The findings highlight new chemical scaffolds with promise for addressing antibiotic resistance and inform future antimicrobial development and testing workflows.

• Light-Inducible RNA-Releasing Proteins for Gene Therapy Cont

  2026-07-22

  This article examines the development of a rationally designed light-inducible RNA-releasing protein (LIRP), enabling precise, reversible control of gene translation in vivo. The approach offers new opportunities for regulated gene therapies, particularly for chronic metabolic and retinal diseases requiring on-demand transgene activity.

• hiPSC-Derived Intestinal Organoids Advance CYP2C19 Substrate

  2026-07-22

  This study introduces a refined protocol for generating human induced pluripotent stem cell-derived intestinal organoids, enabling more accurate in vitro modeling of drug absorption and metabolism. The work specifically addresses the limitations of traditional models for pharmacokinetic studies of CYP2C19 substrates, offering a platform with improved physiological relevance for evaluating drug metabolism.

• Staurosporine: Broad-Spectrum Kinase Inhibitor for Cancer Re

  2026-07-21

  Staurosporine is a potent, broad-spectrum serine/threonine protein kinase inhibitor widely used in cancer research and apoptosis studies. Its precise inhibition profile and solubility in DMSO enable robust modeling of kinase pathways and cell death mechanisms.

• Light-Inducible RNA Control: A New Gene Therapy Paradigm

  2026-07-21

  The reference study introduces a rationally engineered light-inducible RNA-releasing protein (LIRP), enabling reversible, light-dependent translational regulation of therapeutic genes in vivo. This innovation advances optogenetic gene therapy by allowing precise spatial and temporal control of transgene activity in clinically relevant tissues, with potential impact for chronic disease treatment and safety in retinal therapies.

• Toremifene in Breast Cancer: Two Decades of Clinical Insight

  2026-07-20

  This review synthesizes 20 years of clinical experience with toremifene, a selective estrogen receptor modulator, in estrogen receptor–positive breast cancer. The findings illuminate the evolution of endocrine therapy, biomarker-driven patient stratification, and the ongoing role of SERMs versus aromatase inhibitors.

• Clarithromycin and CYP3A: Redefining Drug Interaction Resear

  2026-07-20

  Explore how Clarithromycin, a potent CYP3A inhibitor, is transforming drug-drug interaction research—especially in cardiovascular and statin metabolism studies—by bridging mechanistic understanding with practical protocol guidance. This thought-leadership article from APExBIO's scientific marketing team contextualizes Clarithromycin's role beyond standard product descriptions, integrating mechanistic insights, translational relevance, and strategic recommendations for researchers.

• Pregnenolone Carbonitrile: Strategic Leverage in Liver Prote

  2026-07-19

  This thought-leadership article explores how Pregnenolone Carbonitrile (PCN) enables mechanistic and translational advances in hepatic detoxification, fibrosis, and injury models. Bridging recent mechanistic findings with practical guidance, it empowers researchers to optimize rodent preclinical workflows and positions PCN as a versatile tool beyond standard xenobiotic metabolism research.

• Letrozole as a Non-Steroidal Aromatase Inhibitor: Molecular

  2026-07-18

  Explore how Letrozole, a potent non-steroidal aromatase inhibitor, advances estrogen receptor alpha downregulation and FSH release modulation in breast cancer research. This article delivers unprecedented molecular insight and practical guidance for leveraging Letrozole’s unique properties in translational studies.

• SNS-032 (BMS-387032): Applied Protocols in Cancer and Virolo

  2026-07-17

  SNS-032 (BMS-387032) offers exceptional selectivity for CDK2, CDK7, and CDK9, enabling precise dissection of cell cycle and transcriptional control in cancer and virus-host studies. Its robust, data-backed performance in apoptosis induction, transcriptional blockade, and advanced antiviral assays sets it apart for both oncology and infectious disease research.

• ECL Western Blotting Substrate: Technical Use & QC Guidance

  2026-07-17

  ECL Western Blotting Substrate (SKU K2187) addresses the need for sensitive, nonradioactive detection of horseradish peroxidase-labeled proteins in chemiluminescent Western blot assays. It is optimal for workflows in molecular biology, cancer biology protein analysis, and signal transduction pathway research, but is not compatible with fluorescent or radioisotopic detection methods.

• L-Glutathione Reduced: Molecular Roles in Redox Regulation a

  2026-07-16

  Uncover the advanced biochemical mechanisms of L-Glutathione Reduced and its pivotal applications in cancer metabolism research. This comprehensive analysis offers new assay insights and protocol strategies for investigating redox homeostasis.

• Comparative Gene Expression Reveals Claustrum Subdivisions i

  2026-07-16

  This study delivers a cross-species molecular and cytoarchitectural comparison of the mammalian claustrum, identifying evolutionarily conserved subdivisions based on gene expression. The findings establish a framework for harmonizing structural and functional brain research across diverse mammalian models, advancing translational neuroscience.

• MK-1775 (Wee1 Kinase Inhibitor): Protocols and In Vitro Insi

  2026-07-15

  MK-1775, a potent Wee1 kinase inhibitor from APExBIO, enables precise abrogation of the G2 DNA damage checkpoint and strategic sensitization of p53-deficient tumor cells. Learn how to deploy advanced protocols, troubleshoot key bottlenecks, and leverage the latest in vitro metrics for robust cancer research outcomes.

15750 records 1/1050 page Next 12345 下5页 Last page